Amikacin sulfate 325 mg/mL equivalent to 250 mg/mL Amikacin - Suchergebnisse

pfizer australia pty ltd - amikacin, quantity: 500 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; water for injections; sodium metabisulfite - dbl amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,dbl amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intraabdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Israel - Englisch - Ministry of Health

amikacin - medo

a.l. medi-market ltd. - amikacin as sulfate - solution for injection / infusion - amikacin as sulfate 250 mg / 1 ml - amikacin - amikacin - medo is indicated in the short-term treatment of gram-negative organisms, including pseudomonas and some gram-positive organisms.sensitive gram-negative organisms include; pseudomonas aeruginosa, escherichia coli., indole-positive and indole-negative proteus spp., klebsiella, enterobacter and serratia spp., minea-herralae, citrobacter freundii, salmonella, shigella, acinetobacter and providencia spp.the principal gram-positive organism sensitive to amikacin is staphylococcus aureus, including some methicillin-resistant strains. amikacin - medo has some activity against other gram-positive organisms including certain strains of streptococcus pyogenes, enterococci and diplococcus pneumoniae.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

amikin

bristol-myers squibb (nz) limited - amikacin sulfate equivalent to 250 mg/ml of amikacin - solution for injection - 500 mg/2ml - active: amikacin sulfate equivalent to 250 mg/ml of amikacin excipient: sodium bisulfite sodium citrate dihydrate sulfuric acid water for injection